BR112019024602A2 - ensaio para doença associada à célula de plasma - Google Patents

ensaio para doença associada à célula de plasma Download PDF

Info

Publication number
BR112019024602A2
BR112019024602A2 BR112019024602A BR112019024602A BR112019024602A2 BR 112019024602 A2 BR112019024602 A2 BR 112019024602A2 BR 112019024602 A BR112019024602 A BR 112019024602A BR 112019024602 A BR112019024602 A BR 112019024602A BR 112019024602 A2 BR112019024602 A2 BR 112019024602A2
Authority
BR
Brazil
Prior art keywords
assay
sample
plasma cell
associated disease
cell associated
Prior art date
Application number
BR112019024602A
Other languages
English (en)
Inventor
Wallis Gregg
Geir Hughes Richard
Harding Stephen
Original Assignee
The Binding Site Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59220595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019024602(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Binding Site Group Ltd filed Critical The Binding Site Group Ltd
Publication of BR112019024602A2 publication Critical patent/BR112019024602A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

o pedido proporciona um método para identificar ou o monitorar uma doença associada às células do plasma, compreendendo purificar as cadeias leves livres de imunoglobulina (flcs) a partir de uma amostra de um sujeito com anticorpos específicos anti-flc ou fragmentos dos mesmos e submeter a amostra purificada a uma técnica de espectrometria de massa para identificar a presença de um ou mais picos correspondentes a uma ou mais flcs monoclonais na amostra.
BR112019024602A 2017-05-23 2018-05-23 ensaio para doença associada à célula de plasma BR112019024602A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1708262.9A GB201708262D0 (en) 2017-05-23 2017-05-23 Assay for plasma cell associated disease
PCT/GB2018/051401 WO2018215768A1 (en) 2017-05-23 2018-05-23 Assay for plasma cell associated disease

Publications (1)

Publication Number Publication Date
BR112019024602A2 true BR112019024602A2 (pt) 2020-06-09

Family

ID=59220595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024602A BR112019024602A2 (pt) 2017-05-23 2018-05-23 ensaio para doença associada à célula de plasma

Country Status (12)

Country Link
US (2) US20200096520A1 (pt)
EP (2) EP4071478A1 (pt)
JP (2) JP7284713B2 (pt)
KR (2) KR20230117646A (pt)
CN (1) CN110945360A (pt)
AU (1) AU2018274704B2 (pt)
BR (1) BR112019024602A2 (pt)
CA (1) CA3064521A1 (pt)
DK (1) DK3631452T3 (pt)
ES (1) ES2924870T3 (pt)
GB (1) GB201708262D0 (pt)
WO (1) WO2018215768A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511716A1 (en) * 2018-01-16 2019-07-17 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
CA3139862A1 (en) 2019-05-10 2020-11-19 The Binding Site Group Limited Mass spectrometry calibrator
GB201916030D0 (en) 2019-11-04 2019-12-18 Binding Site Group Ltd Method of detecting or monitoring minimal residual disease
WO2021118353A1 (en) * 2019-12-11 2021-06-17 Erasmus University Medical Center Rotterdam Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法
WO2023107473A1 (en) * 2021-12-07 2023-06-15 Dana-Farber Cancer Institute, Inc. Identifying monoclonal gammopathies in a high-risk population for hematological malignancies
CN115684606B (zh) * 2022-10-21 2023-11-28 南方医科大学珠江医院 一种m蛋白检测的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
IT1216698B (it) 1988-04-01 1990-03-08 New Scient Co Spa Metodo per la determinazione della presenza di catene leggere libere in campioni di urina, complesso di preparati per l'esecuzione del metodo, e relativo reagente.
ES2233980T3 (es) 1995-11-03 2005-06-16 The Binding Site Limited Produccion de anticuerpos.
WO1999060024A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US7786273B2 (en) 2005-03-14 2010-08-31 Medimmune, Llc Macromolecules comprising a thioether cross-link
GB0914535D0 (en) 2009-08-19 2009-09-30 Binding Site Group The Ltd Prognosis assay
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
US10175242B2 (en) 2014-02-28 2019-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
KR101969121B1 (ko) * 2014-10-28 2019-04-15 에스케이텔레콤 주식회사 시스테인 조작된 항체
WO2017053932A1 (en) * 2015-09-24 2017-03-30 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
GB201603291D0 (en) 2016-02-25 2016-04-13 Binding Site Group The Ltd Antibodies

Also Published As

Publication number Publication date
EP4071478A1 (en) 2022-10-12
KR20200008620A (ko) 2020-01-28
KR20230117646A (ko) 2023-08-08
EP3631452A1 (en) 2020-04-08
CN110945360A (zh) 2020-03-31
US20200096520A1 (en) 2020-03-26
CA3064521A1 (en) 2018-11-29
WO2018215768A1 (en) 2018-11-29
AU2018274704A1 (en) 2019-12-12
DK3631452T3 (da) 2022-08-22
JP7284713B2 (ja) 2023-05-31
JP2023098969A (ja) 2023-07-11
AU2018274704B2 (en) 2024-06-13
KR102564244B1 (ko) 2023-08-07
EP3631452B1 (en) 2022-07-13
US20230080943A1 (en) 2023-03-16
GB201708262D0 (en) 2017-07-05
ES2924870T3 (es) 2022-10-11
JP2020522683A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
BR112019024602A2 (pt) ensaio para doença associada à célula de plasma
BR112017025097A2 (pt) método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
BR112016011027A2 (pt) método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
EA200971124A1 (ru) Множественный анализ образцов крови
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
BR112015014833B8 (pt) Anticorpo isolado ou fragmento de ligação, ácido nucleico, método in vitro, kit e composição de anticorpo
BR112014010955A2 (pt) sistema e método para processar amostras
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
BR112013009376A2 (pt) métodos para determinar isótipos de anticorpos antifármacos
BR112018067435A2 (pt) kit de espectrometria de massa
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
BR112014004543A2 (pt) método de síntese de proteínas
BR112014019168A8 (pt) Método capaz de detectar de forma não degenerada presença ou ausência de analitos em um único volume de amostra e método de detecção da presença ou ausência de cada analito dentre uma pluralidade de analitos
BR112015005887A2 (pt) quantificação de tiroglobulina por espectroscopia de massa
BR112019005129A2 (pt) anticorpos anti-pd-1
WO2015131169A3 (en) Personalized myeloma detection
DK1989544T3 (da) T-celle-testmetode
BR112015000340A2 (pt) método para construir um índice de diversidade e um índice de viabilidade de microorganismos em processamento de amostras
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
BR112022008217A2 (pt) Métodos e dispositivos para sequenciamento
WO2016135246A3 (en) Antibody detection method and system
BR112022024978A2 (pt) Métodos livre de cromatografia líquida para quantificar anticorpos alvo em uma amostra e para quantificar um produto de droga de proteína em uma amostra biológica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]